VLA 84

Drug Profile

VLA 84

Alternative Names: Clostridium difficile vaccine - Valneva/GlaxoSmithKline; Clostridium difficile vaccine - Valneva/Novartis; IC-84; VLA-84

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Bacterial vaccines; Immunotoxins; Protein-vaccines; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Clostridium infections

Highest Development Phases

  • Phase II Clostridium infections

Most Recent Events

  • 12 Apr 2017 Immunogenicity and safety data from a phase II study in Clostridium infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017)
  • 03 Mar 2017 VLA 84 is still at phase II development stage in USA and Germany
  • 28 Feb 2017 VLA 84 is available for licensing as of 23 Feb 2017. http://www.valneva.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top